Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04988386 · ClinicalTrials.gov registry record · Phase 3
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
A Phase 3 study of Amyloid Cardiomyopathy, Transthyretin-Related, sponsored by Eidos Therapeutics, a BridgeBio company.
- Active
- Registry status
- Phase 3
- Development phase
- 389
- Enrollment target
- 20
- Study locations
NCT04988386: Active Phase 3 study of Amyloid Cardiomyopathy, Transthyretin-Related, sponsored by Eidos Therapeutics, a BridgeBio company.
NCT04988386 is a Phase 3 study of Amyloid Cardiomyopathy, Transthyretin-Related that is active but no longer recruiting, run by Eidos Therapeutics, a BridgeBio company. The registered enrollment target is 389 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04988386, a Phase 3 study of Amyloid Cardiomyopathy, Transthyretin-Related, is active but no longer recruiting, sponsored by Eidos Therapeutics, a BridgeBio company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 389 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Primary Outcome
Incidence of each treatment-emergent adverse events measured over 60 Months or study completion
Conditions Studied
Interventions
- DRUG Acoramidis (AG10)
Study Locations (20)
New York
- New York University Langone Health - New York
- Columbia University Irving Medical Center - New York
- Laurelton Heart Specialists - Rosedale
- Montefiore Medical Center at Hutchinson - The Bronx
Illinois
- Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
- NorthShore University Health System - Evanston
Missouri
- Saint Luke's Hospital of Kansas City - Kansas City
- Washington University - St Louis
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
California
- Cedars-Sinai Medical Center - Los Angeles
Colorado
- University of Colorado Hospital - Anschutz Medical Campus - Aurora
Maryland
- MedStar Medical Group Cardiology at Franklin Square - Baltimore
Massachusetts
- Boston University Medical Center General Clinical Research Unit - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2028-05-15 |
| Phase | Phase 3 |
What the registry record for NCT04988386 still lists
NCT04988386 is an interventional study that assigns participants to a tested intervention. The registered 389 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Amyloid Cardiomyopathy, Transthyretin-Related appearing as the primary indexed condition, and to 1 intervention - of which Acoramidis (AG10) is the first listed.
NCT04988386 names 20 study sites across 13 states, led by New York, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT04988386 about?
NCT04988386 is a clinical study titled "Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants". Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
What is the current status of trial NCT04988386?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 389 participants. The study started on 2021-10-27. Estimated completion is 2028-05-15.
What conditions does trial NCT04988386 study?
This clinical trial studies the following conditions: Amyloid Cardiomyopathy, Transthyretin-Related.
What interventions are being tested in trial NCT04988386?
The interventions under investigation include: Acoramidis (AG10) (DRUG).
Who is sponsoring clinical trial NCT04988386?
This trial is sponsored by Eidos Therapeutics, a BridgeBio company, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04988386 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04988386's enrollment target sits among peer trials
389 973rd of 2000 higher than 1,028 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05431088 · 389 participants · Phase 2
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI